Hem › Ateroskleros › Texas
Kliniska studier för Ateroskleros i Texas
11 studier för Ateroskleros söker deltagare vid platser i Texas.
Städer i Texas
- Houston10 studier
- Dallas7 studier
- Amarillo6 studier
- The Woodlands6 studier
- San Antonio5 studier
- El Paso4 studier
- McAllen4 studier
- McKinney3 studier
- Mesquite3 studier
- Austin3 studier
- Fort Worth3 studier
Officiell studietext (engelska)
A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Horizon Clinical Research Group, Cypress
- Cardiovascular Specialists of Willowbrook, Houston
- Texas Cardiology Associates of Houston, Kingwood
- och 2 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 30 sep. 2026 · NCT07783802A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events
- Southwest Family Medicine Associates, Dallas
- East Texas Cardiology PA, Houston
- Cardiovascular Specialists of Willowbrook, Houston
- och 1 fler
RekryterarFas 2
Ålder 18 och äldre · Alla kön · Uppdaterad 29 sep. 2026 · NCT07448038Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- PharmaTex Research, Amarillo
- St. David's Heart & Vascular PLLC dba Austin Heart, Austin
- Velocity Clinical Research, Austin, Austin
- och 18 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 24 sep. 2026 · NCT07157774Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- PharmaTex Research, LLC, Amarillo
- Austin Heart, Austin
- Velocity Clinical Research - Austin, Austin
- och 22 fler
RekryterarFas 3
Ålder 45 till 99 · Alla kön · Uppdaterad 22 sep. 2026 · NCT07037433A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
- PharmaTex Research, LLC, Amarillo
- Pulse Care Heart and Vascular, Carrollton
- DM Clinical Research - Dallas, Tomball
RekryterarFas 2
Ålder 18 till 80 · Alla kön · Uppdaterad 22 sep. 2026 · NCT07521007Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
- Cussimanio Research Group LLC, Austin
- Research Management, Inc., Austin
- MW Clinical Research Center, Beaumont
- och 22 fler
RekryterarFas 2/3
Ålder 18 och äldre · Alla kön · Uppdaterad 21 sep. 2026 · NCT05485961A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
- Research Site, Amarillo
- Research Site, Beaumont
- Research Site, Brownsville
- och 33 fler
RekryterarFas 3
Ålder 18 och äldre · Alla kön · Uppdaterad 24 aug. 2026 · NCT07000357Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
- PharmaTex Research LLC, Amarillo
- Kelsey Seybold Research Foundation, Houston
- Northwest Houston Clinical Research PLLC, Tomball
RekryterarFas 3
Ålder 18 till 80 · Alla kön · Uppdaterad 7 aug. 2026 · NCT06813911Pelacarsen Roll-over Extension Program
- Plano Primary Care Clinic, Allen
- Pharma Tex Research, Amarillo
- SW Family Medicine Associates, Dallas
- och 8 fler
RekryterarFas 3
Ålder 18 till 100 · Alla kön · Uppdaterad 29 juli 2026 · NCT06875973Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
- VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX, Dallas
- Michael E. DeBakey VA Medical Center, Houston, TX, Houston
RekryterarFas 4
Ålder 18 och äldre · Alla kön · Uppdaterad 17 dec. 2025 · NCT02915198Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
- UT Health Houston, Houston
RekryterarFas 2
Ålder 40 och äldre · Alla kön · Uppdaterad 17 dec. 2025 · NCT05488431Från ClinicalTrials.gov, data hämtad 3 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.